Fibrocell to Present at Phacilitate Leaders World 2019
January 16 2019 - 8:00AM
Fibrocell Science, Inc. (NASDAQ: FCSC), a gene therapy company
focused on transformational autologous cell-based therapies for
skin and connective tissue diseases, today announced that John
Maslowski, President and Chief Executive Officer, will present at
Phacilitate Leaders World 2019 on Wednesday, January 23 at 2:05 pm
EST in Miami, Florida. Mr. Maslowski will discuss FCX-007, the
company’s gene therapy candidate for the treatment of recessive
dystrophic epidermolysis bullosa (RDEB), a devastating genetic skin
disease with a high mortality rate. The presentation is part of the
conference’s program focused on “Overcoming Obstacles In Vivo: The
Road to Commercial Viability and Continuing Clinical Success in
Viral Gene Therapy.”
About
Fibrocell
Fibrocell is an autologous cell and gene therapy
company translating personalized biologics into medical
breakthroughs for diseases affecting the skin and connective
tissue. Fibrocell's most advanced product candidate, FCX-007,
is the subject of a Phase 1/2 clinical trial for the treatment of
RDEB. Fibrocell is also developing FCX-013, the Company's clinical
stage candidate for the treatment of moderate to severe localized
scleroderma. Fibrocell's gene therapy portfolio is being
developed in collaboration with Intrexon Corporation (NASDAQ: XON),
a leader in synthetic biology. For more information, visit
www.fibrocell.com or follow Fibrocell on Twitter at @Fibrocell.
Trademarks
Fibrocell®, the Fibrocell logo, and Fibrocell
Science® are trademarks of Fibrocell Science, Inc. and/or its
affiliates. All other names may be trademarks of their
respective owners.
Investor & Media Relations
Contact:Karen Casey484.713.6133kcasey@fibrocell.com
Fibrocell Science (NASDAQ:FCSC)
Historical Stock Chart
From Mar 2024 to Apr 2024
Fibrocell Science (NASDAQ:FCSC)
Historical Stock Chart
From Apr 2023 to Apr 2024